MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Natera Inc

Отворен

СекторЗдравеопазване

151.55 -0.34

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

151.76

Максимум

155.06

Ключови измерители

By Trading Economics

Приходи

-22M

-54M

Продажби

36M

476M

EPS

-0.41

Марж на печалбата

-11.295

Служители

4,424

EBITDA

-27M

-46M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+26.23% upside

Дивиденти

By Dow Jones

Следващи печалби

8.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-890M

20B

Предишно отваряне

151.89

Предишно затваряне

151.55

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Natera Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.05.2024 г., 14:49 ч. UTC

Печалби
Горещи акции

Stocks to Watch Friday: TSMC, Novavax, Nvidia -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Natera Inc Прогноза

Ценова цел

By TipRanks

26.23% нагоре

12-месечна прогноза

Среден 195 USD  26.23%

Висок 251 USD

Нисък 160 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за Natera Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

16

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

147.24 / N/AПодкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.